10X GENOMICS INC's ticker is TXG and the CUSIP is 88025U109. A total of 341 filers reported holding 10X GENOMICS INC in Q2 2021. The put-call ratio across all filers is 0.17 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $328,131 | -97.4% | 6,585 | -97.0% | 0.00% | -100.0% |
| Q2 2023 | $12,865,746 | +1503.9% | 221,251 | +909.2% | 0.00% | – |
| Q4 2022 | $802,163 | -0.2% | 21,923 | -2.1% | 0.00% | – |
| Q3 2022 | $804,000 | +232.2% | 22,393 | +354.9% | 0.00% | – |
| Q2 2022 | $242,000 | -17.4% | 4,923 | +26.6% | 0.00% | – |
| Q1 2022 | $293,000 | -94.2% | 3,890 | -88.4% | 0.00% | -100.0% |
| Q4 2021 | $5,080,000 | -12.1% | 33,637 | -14.7% | 0.00% | 0.0% |
| Q3 2021 | $5,782,000 | -24.2% | 39,433 | +4.2% | 0.00% | -25.0% |
| Q2 2021 | $7,628,000 | +8.5% | 37,839 | +2.4% | 0.00% | -20.0% |
| Q1 2021 | $7,030,000 | +4134.9% | 36,950 | +3632.3% | 0.01% | – |
| Q4 2020 | $166,000 | -88.1% | 990 | -90.3% | 0.00% | -100.0% |
| Q3 2020 | $1,393,000 | +23116.7% | 10,185 | +16327.4% | 0.00% | – |
| Q2 2020 | $6,000 | +200.0% | 62 | +55.0% | 0.00% | – |
| Q1 2020 | $2,000 | -33.3% | 40 | 0.0% | 0.00% | – |
| Q4 2019 | $3,000 | – | 40 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 1,358,528 | $49,504,760 | 100.00% |
| Meritech Capital Associates V L.L.C. | 1,061,682 | $38,687,692 | 9.44% |
| Decheng Capital Management III (Cayman), LLC | 359,554 | $13,102,148 | 4.90% |
| Sands Capital Ventures, LLC | 481,770 | $17,556 | 4.81% |
| Whitford Management LLC | 58,310 | $2,124,803 | 2.88% |
| FINANCIAL CONSULATE, INC | 156,457 | $5,701,293 | 1.99% |
| SRS Investment Management, LLC | 3,005,427 | $109,517,760 | 1.98% |
| BRANDYWINE MANAGERS, LLC | 11,208 | $408,420 | 1.43% |
| ARK Investment Management | 4,316,567 | $157,295,701 | 1.36% |
| Nikko Asset Management Americas, Inc. | 2,177,988 | $79,365,883 | 1.14% |